 |
Strategies for Preventing and Treating Uncontrolled Perioperative Bleeding CME Bruce D. Spiess, MD, FAHA Author Information and Disclosures Release Date: April 14, 2008; Valid for credit through April 14, 2009 | Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity, Strategies for Preventing and Treating Uncontrolled Perioperative Bleeding, is based on a series of webinar meetings held on the topic of hemostatic surgical challenges.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Educational Concepts in Medicine. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Discuss specific patient types who may be at increased risk for perioperative bleeding and complications from acquired coagulopathy
- Explain the essentials of
surgical hemostasis and current guidelines for achieving balance between bleeding and clotting
- Explain the benefits and risks of blood products as a therapeutic modality
- Describe available nontransfusional treatment modalities for achieving operative hemostasis
Author Disclosures Bruce D. Spiess, MD, FAHA
Disclosure: Consultant: Bayer Pharmaceuticals Corporation, Synthetic Blood International, Inc.; Fees for non-CME services received directly from a commercial interest: Bayer Pharmaceuticals Corporation; Contracted Research: Synthetic Blood International, Inc.; Ownership Interest: Synthetic Blood International, Inc.
Domenic A. Sica, MD
Disclosure: Consultant: King Pharmaceuticals
Eliot A. Brinton, MD
Disclosure: Consultant: Abbott Laboratories, GlaxoSmithKline, Merck & Co., Inc., Reliant Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., Wyeth Pharmaceuticals; Fees for non-CME services received directly from a commercial interest or their agents: Abbott Laboratories, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Pfizer
Inc., Reliant Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., Wyeth Pharmaceuticals; Contracted Research: Merck & Co., Inc., Pfizer Inc., Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc.
Howard L. Corwin, MD
Disclosure: Consultant: Johnson & Johnson, The Medicines Company, Ortho Biotech Products, L.P.
Victor A. Ferraris, MD, PhD
Disclosure: Consultant: AstraZeneca Pharmaceuticals L.P., Aventis, Bayer Pharmaceuticals Corporation, The Medicines Company; Contracted Research: Aventis, Bayer Pharmaceuticals Corporation, BioMarin Pharmaceutical Inc., Guilford Pharmaceuticals, The Medicines Company, Medtronic
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner
have with commercial interests related to the content of this CME activity:
PIM Clinical Reviewers: Trace Hutchison, PharmD; Jan Hixon, RN, BSN, MSN; Linda Graham, RN, BSN; and Jan Schultz, RN, BSN, MSN
Disclosure: Have no real or apparent conflicts of interest to report
ECM: Bart Zoni, Executive Director; Patrick Crowley, Senior Director of Operations
Disclosure: Have no real or apparent conflicts of interest to
report
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM), the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
